Real-World Use of Adjuvant Nivolumab for Resected Stage III–IV Melanoma: 2-Year Analysis of AdjuMel - Poll - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Evaluation of Adjuvant Nivolumab in Patients with Resected Stage III–IV Melanoma: Two-Year Findings from the AdjuMel Study

  • By

  • Stéphane Dalle

  • Philippe Saiag

  • Céleste Lebbé

  • Jean-Jacques Grob

  • Brigitte Dréno

  • Sophie Dalac

  • Bernard Asselain

  • François Skowron

  • Sophie Darras

  • Nicolas Jovenin

  • Gaëlle Quereux

  • Amir Khammari

  • Capucine Rieuf

  • Florence Brellier

  • Laurent Mortier

  • August 29, 2026

Share

Original Source(s)

Related Content